
    
      This phase 2 study of donafenib, an oral multikinase inhibitor that targets Raf kinase and
      receptor tyrosine kinases, is to assess efficacy and safety in patients with
      131I-refractory/resistant differentiated thyroid cancer.The study is a
      randomised,multicentre,open-label study.
    
  